ストックスクリーナーアプリを入手
35.50
0.00%
0.00
アフターアワーズ：
36.60
1.10
+3.10%
Stoke Therapeutics Inc (STOK) 最新ニュース
Stoke Therapeutics (NASDAQ:STOK) Upgraded to Strong-Buy at Wolfe Research - MarketBeat
Risk Analysis: What is the earnings history of Stoke Therapeutics IncJuly 2025 Outlook & Weekly High Return Opportunities - baoquankhu1.vn
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - PharmiWeb.com
Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK) - TechStock²
Wolfe Research Initiates Coverage on Stoke Therapeutics (STOK) w - GuruFocus
Wolfe Research Initiates Coverage of Stoke Therapeutics (STOK) with Outperform Recommendation - Nasdaq
Forecasting The Future: 5 Analyst Projections For Stoke Therapeutics - Benzinga
A Look At Stoke Therapeutics (STOK) Valuation After Recent Share Price Momentum - Yahoo Finance
Stoke Therapeutics Shares Poised for Pivotal Clinical Updates - AD HOC NEWS
Is Stoke Therapeutics Inc. stock a good pick for beginnersJuly 2025 Big Picture & Real-Time Stock Entry Alerts - mfd.ru
What is the PEG ratio of Stoke Therapeutics Inc.July 2025 Earnings & AI Enhanced Trading Alerts - mfd.ru
Stoke Therapeutics, Inc. (STOK) Stock Analysis: Impressive Revenue Growth and Promising Upside - DirectorsTalk Interviews
Is Stoke Therapeutics Inc. in a long term uptrend2025 Price Momentum & Free Low Drawdown Momentum Trade Ideas - mfd.ru
STOK: Cantor Fitzgerald Analyst to Host Conference Call with Man - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 10.2%Here's Why - MarketBeat
45,205 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Principal Financial Group Inc. - MarketBeat
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Liquidity Mapping Around (STOK) Price Events - Stock Traders Daily
Growth Value: What are the analyst revisions for MESAIs Stoke Therapeutics Inc stock a good investment in YEARPortfolio Gains Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Stoke Therapeutics spotlights durable Dravet gains, Phase 3 timeline, and new ADOA program at summit - MarketBeat
Stoke Therapeutics, Inc. (STOK) Stock Analysis: Unveiling a 31% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Ideas Watch: What is the earnings history of Stoke Therapeutics IncQuarterly Trade Review & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
STOK: Four-year data show durable seizure reduction and cognitive gains, with phase 3 readout expected 2027 - TradingView
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Mo - pharmiweb.com
Stoke Therapeutics announces first patient dosed in Phase 1 study of STK-002 - marketscreener.com
Is Stoke Therapeutics Inc. a cyclical or defensive stockQuarterly Earnings Report & Daily Technical Forecast Reports - mfd.ru
Stoke Therapeutics announced that the dose-escalation phase for the first four cohorts of its research project will continue into 2026 and early 2027. - Bitget
Stoke Therapeutics Announces First Patient Dosed In Phase 1 Study Of Stk-002 - TradingView
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) - Business Wire
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Earnings: What is the PEG ratio of Stoke Therapeutics IncJuly 2025 Movers & Fast Gain Stock Trading Tips - baoquankhu1.vn
Guggenheim Upgrades Stoke Therapeutics (NASDAQ:STOK) to "Strong-Buy" - MarketBeat
Why (STOK) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Earnings Recap: How does Stoke Therapeutics Inc score in quality rankingsShare Buyback & Target Return Focused Stock Picks - baoquankhu1.vn
Penserra Capital Management LLC Acquires New Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics stock jumps after Guggenheim initiates with Buy rating By Investing.com - Investing.com South Africa
Stoke Therapeutics stock jumps after Guggenheim initiates with Buy rating - Investing.com
Guggenheim Initiates Coverage on Stoke Therapeutics With Buy Rating, $60 Price Target - marketscreener.com
Guggenheim initiates Stoke Therapeutics stock with Buy rating on Dravet drug - Investing.com Canada
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - pharmiweb.com
Biotech CEO to outline Stoke Therapeutics’ outlook at Guggenheim - Stock Titan
Aug Action: Can Stoke Therapeutics Inc navigate macro headwindsEarnings Miss & Growth-Oriented Investment Plans - baoquankhu1.vn
Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Sentiment Watch: Should I hold or sell Stoke Therapeutics Inc nowJuly 2025 Opening Moves & Weekly Breakout Watchlists - baoquankhu1.vn
Breakouts Watch: Does FULT outperform in volatile marketsJuly 2025 Opening Moves & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Commit To Buy Stoke Therapeutics At $20, Earn 20.2% Annualized Using Options - Nasdaq
Stoke Therapeutics, Inc. (STOK) Investor Outlook: A Promising 27.53% Upside Potential In Biotech - DirectorsTalk Interviews
Stoke Therapeutics (NASDAQ:STOK) Trading 6.2% HigherHere's What Happened - MarketBeat
Stoke Therapeutics Expands with New Long-Term Waltham Headquarters - TipRanks
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA - Finviz
Stoke Therapeutics Shares Face Pressure from Strategic Expansion - AD HOC NEWS
Understanding Momentum Shifts in (STOK) - Stock Traders Daily
Should value investors consider Stoke Therapeutics Inc2025 Volatility Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Stoke Therapeutics (STOK) Stock Analysis: Unveiling Growth Potential with a 23.54% Upside - DirectorsTalk Interviews
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
Stoke Therapeutics, Inc. $STOK is Skorpios Trust's Largest Position - MarketBeat
1.52%
1.68%
大文字化:
|
ボリューム (24 時間):